SUPPLEMENTARY INFORMATION

Rapid Screening of COVID-19 Disease Directly from Clinical Nasopharyngeal Swabs using the MasSpec Pen Technology

Kyana Y. Garza^{1†}, Alex Ap. Rosini Silva^{2†}, Jonas R. Rosa², Michael F. Keating¹, Sydney C. Povilaitis¹, Meredith Spradlin¹, Pedro H. Godoy Sanches², Alexandre Varão Moura², Junier Marrero Gutierrez², John Q. Lin¹, Jialing Zhang¹, Rachel J. DeHoog¹, Alena Bensussan¹, Sunil Badal¹, Danilo Cardoso², Pedro Henrique Dias Garcia², Lisamara Dias de Oliveira Negrini³, Marcia Ap. Antonio⁴, Thiago C. Canevari⁵, Marcos N. Eberlin⁵, , Robert Tibshirani⁶, Livia S. Eberlin^{1*}, Andreia M. Porcari^{2*}

¹ Department of Chemistry, The University of Texas at Austin, Austin, TX, 78712

² MS4Life Laboratory of Mass Spectrometry, Health Sciences Postgraduate Program, São Francisco University, Bragança Paulista, São Paulo, Brazil

³ Municipal Department of Health, Bragança Paulista, Sao Paulo, Brazil

⁴ Integrated Unit of Pharmacology and Gastroenterology, UNIFAG, Bragança Paulista, Sao Paulo, Brazil

⁵ Department of Material Engineering and Nanotechnology, Mackenzie Presbyterian University, São Paulo, Sao Paulo, Brazil

⁶Department of Biomedical Data Science, Stanford University, Stanford, CA 94305

[†]Equally contributed to this work

^{*} to whom correspondence should be addressed: liviase@utexas.edu; andreia.porcari@usf.edu.br

Table of Contents

Supplementary Methods

Supplementary Figure 1. Comparison of mass spectra obtained using ESI or solvent-assisted inlet ionization as the ionization mechanism.

Supplementary Figure 2. Mass spectra obtained from the MasSpec Pen-ESI analysis of a nylon flock swab containing a lipid standard.

Supplementary Figure 3. Comparison of mass spectra acquired from the analysis of swabs with and without heat inactivation.

Supplementary Table 1. Demographic and clinical information for symptomatic negative patients in the withheld set for Classifier 1 and training set of Classifier 2.

Supplementary Table 2. Overall classification results and agreement with clinical PCR diagnosis for Classifier 1 and 2.

Supplementary Table 3. Identification, observed m/z, and mass error for ions selected by Lasso as indicative of negative and positive COVID-19 infection.

Supplementary Methods

Engineering the lab-built ESI housing and sprayer

Aluminum blocks and rubber gaskets were machined onto the source to create a vacuum seal when interfaced to the mass spectrometer, and a metal adapter was machined into the bottom of the aluminum block to connect a vacuum tube attached to an external rough pump (Edwards Vacuum). Additionally, a ceramic block was engineered and added to hold the lab-built ESI sprayer. The lab-built sprayer consists of a metal capillary (7 in, 0.62 in OD, 0.16 in ID, New England Small Tube Corporation) concentric with a ceramic tube (10 in, 0.125 in OD, 0.063 in ID, Omega Engineering, Inc.) through which N₂ gas flows acting as a sheath gas, a plastic union tee (0.25 in, Legris) to which a gas tube is attached, and two neoprene rubber stoppers each machined with a hole to fit the ceramic tube or metal capillary. A 1.5 m polytetrafluoroethylene (PTFE) tubing and silicone were used to connect the PDMS swab sampling port to the metal capillary of the lab-built sprayer.

Handling and storage of clinical nasal swabs

HydraFlock polyester swabs sterilized by gamma irradiation (Puritan Medical Products) were shipped to Brazil. A permit to import samples from Brazil to UT Austin was received from the Brazilian Health Regulatory Agency (ANVISA) and the Center for Disease Control and Prevention (CDC). Prior to shipment, all swabs were heat-inactivated in Brazil at 65°C for 30 min and kept at -20°C until the shipment in dry ice. Experiments were performed at the University of Texas at Austin under Biosafety Level 2 conditions. Swabs were handled by the principal investigator in the biosafety cabinet following biosafety protocols and requirements from the institutional biosafety committee.

Optimization of MasSpec Pen-ESI MS system for analysis of swabs

Various swab tip materials were tested using the MasSpec Pen-ESI MS system, including nylon (Copan Diagnostics) and polyester flock (Puritan Medical Products) swabs. Each swab was dipped in a 13 μ M standard solution of CL 72:4 and analyzed using the MasSpec Pen-ESI system in the negative ion mode,

with the mass spectrum of polyester flock swabs containing minimal interfering ions in the lipid range compared to nylon flock swabs. The interfering ions presented polymer-like distribution and were identified as repeating units of ethylene oxide. Additionally, solvents including methanol, isopropylalcohol, ethanol:ethylacetate (1:1, v/v), CHCl₃:MeOH (1:1, v/v), and CHCl₃:MeOH (2:1, v/v) were tested for compatibility with the MasSpec Pen-ESI MS system.

To evaluate the robustness of the MasSpec Pen-ESI MS system for the detection of lipids from gamma-irradiated polyester flock swabs, swabs dipped in 100 μ L of an equimolar (10 μ M) lipid standard mixture of PE 36:2 (m/z 742.540) and PG 36:2 (m/z 773.539) were analyzed using CHCl₃:MeOH (1:1, v/v) as the solvent, yielding a relative standard deviation of 6.4% (n=10).

To evaluate the effect of heat inactivation of the biological material on the swabs, swabs dipped in a mixture of PG and PE lipid standards were heat-treated for 30 min at 65°C (n=5) to simulate heat-inactivation, while control swabs (n=5) dipped in the same lipid mixture standard were not heat-treated, followed by analysis using the MasSpec Pen-ESI system

MasSpec Pen-ESI MS analysis of clinical nasal swabs

Extraction solvent, solvent volume, and swab type were optimized using the ion trap analyzer of an LTQ Orbitrap XL, while the heat inactivation experiments, reproducibility experiments, and analysis of clinical swabs were performed using the orbitrap mass analyzer of a Q Exactive HF mass spectrometer. MasSpec Pen-ESI MS analysis of swabs was performed in the negative ion mode at a mass range of m/z 100-1500, resolving power of 120,000, and an inlet temperature of 300°C. A voltage of 3.3 kV was applied to the ESI sprayer, and the nitrogen sheath gas pressure was set to 20 psi. The pressure inside the ESI source was approximately 1.4-1.6 mbar for all analyses and experiments. Selected molecular ions were identified by tandem MS and high mass accuracy measurements acquired during MasSpec Pen-ESI MS analyses of swabs on the Q Exactive HF. For the analysis of swabs, chloroform:methanol (CHCl₃:MeOH, 1:1, v/v) was used as the extraction solvent. A new sampling device and tubing and a clean sprayer were used for each analysis to avoid cross-contamination between each analysis.


Statistical analysis

The reproducibility of the MasSpec Pen-ESI system for swab analysis was quantified by calculating the relative standard deviation using the ratio of the intensities of lipid standards, m/z 773.534 (PG 36:2)/m/z 742.539 (PE 36:2) (n=10). To evaluate the effect of heat inactivation on the stability of lipids, a t-test was performed on the intensities of two lipid standards, m/z 742.639 and m/z 773.533, extracted from swabs without heat inactivation (n=5) and swabs heat-inactivated for 30 min at 65°C (n=5) using the MasSpec Pen-ESI system. Lastly, descriptive statistics were also computed for clinical and demographic variables. Categorical variables were expressed as count (percentage), whereas continuous variables were expressed as median (25–75th percentiles). The chi-square test was used to compare categorical variables proportions, and the Mann–Whitney U-test was used to evaluate continuous data.


Supplementary Discussion

Case Studies


Sample 108 was obtained from a patient with preexisting conditions, including obesity and hypertension. This person received a PCR negative diagnosis and was classified as positive by our method. The symptoms included chest CT results suggestive of infection with GGO, consolidations, crazy-paving appearance, and pulmonary commitment (50%), as well as fever and low O₂ saturation levels (<95%). The patient was discharged from the hospital after nine days. Sample 242 was collected from a patitent who received a PCR negative diagnosis and was also classified by our method as negative for viral infection. The patient was hospitalized for three days with symptoms including coughing, sore throat, and dyspnea, whereas her chest CT results were not indicative of an infection.



Supplementary Figure 1. Comparison of mass spectra obtained using the MasSpec Pen with ESI or solvent assisted inlet ionization to analyze a 20 ppm CL 72:4 lipid standard. The top mass spectrum shows the profile obtained using ESI as the ionization mechanism and the bottom spectrum shows the data collected using a solvent-assisted inlet ionization. The singly and doubly charged CL species are labeled in red.



Supplementary Figure 2. Representative mass spectrum from the MasSpec Pen-ESI MS analysis of a nylon flock swab dipped in 20 ppm CL 72:4 (*m/z* 727.510) lipid standard. The doubly charged CL species are labeled in red while the repeating units of ethylene oxide are labeled in black.



Supplementary Figure 3 Comparison of mass spectra of swabs containing a $10 \,\mu\text{M}$ PG $36:2 \,(m/z \,773.533)$ and PE $36:2 \,(m/z \,742.539)$ lipid standard mixture with and without heat inactivation. The mass spectrum on top was obtained from the MasSpec Pen-ESI MS analysis of a swab without heat inactivation while the bottom shows the profile for a swab that had been heat-inactivated at 60°C for 30 min. Both insets are a zoom of $m/z \,720-800$ range to show the detection of the lipid standards.

Supplementary Table 1. Demographic and detailed clinical information, including clinical diagnosis, hospitalization, chest CT, and symptom information, for the 26 symptomatic negative patients in the withheld set of samples used in Classifier 1 and in the training set for Classifier 2.

Discharged	0	0	64	NEG	NEG	267	Symptomatic Negative
Discharged	0	0	2	POS	NEG	266	Symptomatic Negative
Discharged	0	0	ယ	NEG	NEG	265	Symptomatic Negative
Discharged	0	0	2	POS	NEG	264	Symptomatic Negative
Discharged	0	0	6	POS	NEG	263	Symptomatic Negative
Discharged	0	0	ω	NEG	NEG	242	Symptomatic Negative
Discharged	0	0	10	POS	NEG	240	Symptomatic Negative
Discharged	0	0	6	POS	NEG	193	Symptomatic Negative
Discharged	0	0	3	NEG	NEG	156	Symptomatic Negative
Death	0	0	4	POS	NEG	152	Symptomatic Negative
Discharged	0	0	7	POS	NEG	151	Symptomatic Negative
Discharged	0	0	7	POS	NEG	149	Symptomatic Negative
Discharged	0	0	8	NEG	NEG	116	Symptomatic Negative
Discharged	0	0	2	POS	NEG	111	Symptomatic Negative
Discharged	0	0	9	POS	NEG	108	Symptomatic Negative
Discharged	0	0	1	POS	NEG	101	Symptomatic Negative
Discharged	0	0	5	POS	NEG	97	Symptomatic Negative
Discharged	0	0	5	POS	NEG	96	Symptomatic Negative
Discharged	0	0	7	POS	NEG	93	Symptomatic Negative
Death	19	19	29	POS	NEG	92	Symptomatic Negative
Discharged	0	0	4	POS	NEG	71	Symptomatic Negative
Discharged	0	0	3	POS	NEG	68	Symptomatic Negative
Discharged	0	0	13	POS	NEG	45	Symptomatic Negative
Discharged	0	0	3	POS	NEG	36	Symptomatic Negative
Death	11	13	15	POS	NEG	34	Symptomatic Negative
Discharged	0	0	2	POS	NEG	30	Symptomatic Negative
Outcome	Mechanical Ventilation Days.	ICU days	Hospitalization Days	$\textbf{RT-PCR (Observed)} \left \textbf{Prediction (classifier I)} \right \textbf{Hospitalization Days}$	RT-PCR (Observed)	ID#	Original Class

						Chest CT Findings		
Original Class	Ш#	Chest C1 Suggestive of viral infection	Ground-Glass Opacity	Consolidations	Ground-Glass Opacity Consolidations Crazy Paving Appearance Reticul	e Reticular Pattern	lar Pattern resence of Pulmonary Commitme % of Pulmonary Commitment	% of Pulmonary Comm
Symptomatic Negative	30	YES	YES	ON	ON	ON	YES	25-50
	34	YES	YES	YES	ON	ON	YES	50
	36	YES	YES	NO	YES	YES	YES	20-50
	45	YES	YES	YES	YES	YES	YES	50
	68	ON	ON	ON	ON	ON	NO	0
	71	YES	YES	YES	ON	ON	YES	50
	92	YES	YES	NO	ON	NO	YES	30-50
	93	YES	YES	YES	YES	NO	YES	60
	96	YES	YES	YES	ON	YES	YES	20-50
	97	YES	YES	YES	YES	YES	YES	30
	101	YES	YES	YES	ON	NO	NO	0
	108	YES	YES	YES	YES	YES	YES	50
	111	YES	YES	YES	ON	NO	YES	50-80
	116	NO	NO	NO	NO	NO	NO	0
Symptomatic Negative	149	YES	YES	YES	NO	NO	YES	50-70
	151	YES	YES	YES	YES	NO	YES	50-80
	152	YES	YES	YES	YES	NO	YES	50
	156	NO	NO	NO	NO	NO	NO	-
Symptomatic Negative	193	YES	YES	YES	YES	NO	YES	50-80
	240	NO	NO	NO	NO	NO	NO	0
Symptomatic Negative	242	NO	NO	NO	NO	NO	NO	0
	263	NO	NO	YES	NO	NO	NO	0
	264	YES	YES	NO	NO	NO	NO	0
Symptomatic Negative	265	NO	NO	NO	NO	NO	NO	0
	266	NO	NO	NO	NO	NO	NO	0
Symptomatic Negative	267	YES	YES	NO	YES	YES	YES	20-50

,	=					Reporte	Reported Symptons				Other information	ation	
Original Class	TD#	Fever	Cough	Myalgia	Sore. Throat	Headache	Coryza	Dyspnea	Loss of smell/taste	O2 Sauration < 95%	COPD presence	Smoker or Ex-smoker	Asthma
Symptomatic Negative	30	YES	YES	NO	NO	NO	NO	YES	YES	YES	NO	NO	NO
Symptomatic Negative	34	ON	YES	ON	YES	NO	ON	YES	NO	ON	ON	ON	NO
Symptomatic Negative	36	YES	NO	NO	NO	NO	NO	YES	NO	YES	NO	NO	NO
Symptomatic Negative	45	ON	NO	YES	ON	NO	NO	YES	NO	NO	NO	ON	NO
Symptomatic Negative	68	YES	NO	NO	NO	NO	NO	YES	YES	YES	NO	NO	NO
Symptomatic Negative	71	YES	NO	NO	YES	NO	NO	NO	YES	YES	NO	NO	NO
Symptomatic Negative	92	NO	YES	NO	NO	NO	NO	YES	NO	NO	NO	NO	NO
Symptomatic Negative	93	NO	YES	NO	NO	NO	NO	YES	YES	NO	NO	NO	NO
Symptomatic Negative	96	NO	YES	NO	NO	NO	NO	YES	NO	NO	YES	YES	NO
Symptomatic Negative	97	YES	NO	NO	YES	NO	YES	NO	NO	NO	NO	NO	NO
Symptomatic Negative	101	YES	NO	NO	NO	NO	NO	NO	NO	YES	NO	NO	YES
Symptomatic Negative	108	NO	YES	NO	NO	NO	NO	NO	NO	YES	NO	NO	NO
Symptomatic Negative	111	NO	YES	NO	NO	NO	NO	NO	YES	YES	NO	NO	NO
Symptomatic Negative	116	NO	NO	NO	NO	NO	NO	YES	YES	NO	NO	NO	NO
Symptomatic Negative	149	YES	NO	NO	YES	NO	NO	NO	NO	NO	NO	NO	NO
Symptomatic Negative	151	NO	YES	NO	YES	YES	NO	YES	YES	YES	NO	NO	NO
Symptomatic Negative	152	YES	NO	NO	NO	NO	NO	YES	YES	NO	NO	YES	NO
Symptomatic Negative	156	NO	YES	NO	YES	NO	NO	YES	NO	NO	NO	NO	YES
Symptomatic Negative	193	YES	NO	YES	NO	NO	NO	NO	YES	YES	NO	NO	NO
Symptomatic Negative	240	YES	YES	NO	NO	NO	YES	YES	NO	NO	NO	YES	NO
Symptomatic Negative	242	NO	YES	NO	YES	NO	YES	NO	NO	NO	NO	NO	NO
Symptomatic Negative	263	YES	YES	NO	NO	NO	NO	YES	NO	NO	NO	NO	NO
Symptomatic Negative	264	YES	YES	NO	YES	NO	NO	YES	NO	NO	NO	NO	NO
Symptomatic Negative	265	YES	YES	NO	NO	NO	NO	YES	NO	NO	NO	NO	NO
Symptomatic Negative	266	YES	YES	NO	NO	NO	NO	YES	NO	NO	NO	NO	NO
Symptomatic Negative	267	NO	YES	NO	NO	NO	NO	YES	NO	NO	NO	NO	NO

Supplementary Table 2. Confusion matrices of the Lasso results for Classifiers 1 and 2.

Classification Model	Sample Set	PCR Diagnosis			<u>M</u>	odel Prediction	and Performan	<u>ce</u>			
			Negative	Positive	Sensitivity (%)	Specificity (%)	Accuracy (%)	NPV (%)	PPV (%)	FNR	FPR
Classifier 1: Asymptomatic Negative vs Symptomatic Positive	Training	Negative	58	9	76.7	86.6	83.5	89.2	71.9	23.3	13.4
	Training	Positive	7	23	76.7	00.0	63.5	09.2	71.9	23.3	13.4
	Validation	Negative	29	5	100.0	85.3	89.6	100.0	73.7	0.0	14.7
-,p	validation	Positive	0	14	100.0	65.5	09.0	100.0	13.1	0.0	14.7
	Withheld Data	Negative	17	9	-	65.4	-	-	-		
Classifier 2: Asymptomatic + Symptomatic	Training	Negative	98	29	81.8	77.2	70 /	92.5	55.4	18.2	22.8
Negative vs Symptomatic Positive	rraining	Positive	8	36	01.0	11.2	78.4	92.5	55.4	10.2	22.0

Supplementary Table 3. Observed m/z, mass error, and identification for the features selected by Lasso for Classifier 1 and 2. Identifications are based on high mass accuracy and/or tandem MS measurements.

Lasso Feature	Observed m/z	Theoretical m/z	Mass Error	Attribution	Formula
415.23	415.226	415.2255	1.204	LPA O-18:4	C21H37O6P [M-H]-
417.24	417.241	417.2412	-0.479	LPA O-18:3	C21H39O6P [M-H]-
418.24	418.244	418.2445	-1.195	Isotope of LPA O-18:3, m/z 417.241	С21Н39О6Р [М-Н]-
422	421.997	-	-	Unidentified	-
446.34	446.336	-	-	Isotope of m/z 445.333, unidentified	-
450.87	450.874	-	-	Unidentified	-
467.32	467.316	467.3143	3.638	LPA O-20:0	
506.32	506.324	506.3252	-2.370	LPE 20:1	C25H50NO7P [M-H]-
508.34	508.341	508.3409	0.197	LPE 20:0	C25H52NO7P [M-H]-
509.34	509.344	509.3442	-0.393	Isotope of LPE 20:0	C25H52NO7P [M-H]-
512.28	512.283	512.2864	-	Unidentified	-
522.28	522.284	522.2838	0.383	LPS 18:1	C24H46NO9P [M-H]-
556.32	556.318	556.3176	0.719	LPC 18:1	C26H52NO7P
600.51	600.514	600.5128	1.998	Cer 36:1	C36H71NO3 [M+C1]-
618.52	618.524	618.5234	0.970	Cer 36:0	C36H73NO4 [M+C1]-
619.29	619.289	619.2889	0.161	LPI 20:4	C29H49O12P [M-H]-
624.52	624.522	-	-	Unidentified	-
629.49	629.492	629.4917	0.477	DG 34:1	C37H70O5 [M+C1]-
635.48	635.482	635.4812	1.259	DG O-36:5	C39H68O4 [M+C1]-
655.51	655.508	655.5074	0.915	DG 36:2	C39H72O5 [M+C1]-
679.51	679.507	679.5074	-0.589	DG O-38:5	C41H72O5 [M+C1]-
680.58	680.576	680.5754	0.882	Cer 42:3	C42H79NO3 [M+C1]-
682.59	682.591	682.5911	-0.147	Cer 42:2	C42H81NO3 [M+C1]-
683.59	683.594	683.5944	-0.585	Isotope of m/z 682.591, Cer 42:2	C42H81NO3 [M+C1]-
684.59	684.588	684.5881	-0.146	Isotope of m/z 682.591, Cer 42:3	C42H81NO4 [M+C1]-
694.59	694.592	694.5911	1.296	Cer 43:3	C43H81NO3 [M+C1]-
697.61	697.61	-	-	Unidentified	-

700.59	700.587	700.5886	-2.284	Cer 44:5	C44H79NO5 [M+Cl]-
703.51	703.507	703.5074	-0.569	DG 40:6	C43H72O5 [M+C1]-
703.6	703.603	-	-	Unidentified	-
710.62	710.623	710.6224	0.844	Cer 44:2	C44H85NO3 [M+Cl]-
714.51	714.508	714.5079	0.140	PE 34:2	C39H74NO8P [M-H]-
718.61	718.613	-	-	Unidentified	-
723.98	723.981	723.9805	0.691	Isotope of m/z 723.479, CL 72:8	C81H142O17P2 [M- 2H]2-
725.53	725.533	725.5362	-4.411	DG 42:7	C45H74O7 [M-H]-
734.53	734.534	734.5342	-0.272	PE 34:0	C39H78NO9P [M-H]-
737.54	737.537	737.5370	0.000	SM 34:1	C39H79N2O6P [M+Cl]-
746.51	746.513	746.5130	0.000	PE O-38:7	C43H74NO7P [M-H]-
750.53	750.528	750.5292	-1.599	HexCer 34:1	C49H77NO9 [M+Cl]-
754.55	754.554	754.5523	2.253	PC O-32:0	C40H82NO7P [M+C1]-
761.53	761.534	761.532	2.626	Isotope of m/z 760.529, PE O-39:7	C44H76NO7P [M-H]-
769.54	769.535	769.5389	-	Unidentified	-
770.57	770.570	770.5705	-0.649	PE 38:2	C43H82NO8P [M-H]-
771.57	771.573	771.574	-1.296	Isotope of m/z 770.570, PE 38:2	C43H82NO8P [M-H]-
773.53	773.534	773.5338	0.259	PG 36:2	C42H79O10P [M-H]-
776.56	776.559	776.5600	-1.288	PE O-40:6	C45H80NO7P [M-H]-
794.51	794.508	794.5108	-3.524	PE 36:2	C41H78NO9P [M+C1]-
794.53	794.529	-	-	Unidentified	-
808.5	808.504	808.5054	-1.732	PE O-40:8	C45H76NO7P [M+C1]-
845.61	845.610	845.611	-1.183	Isotope of m/z 844.607, PS 40:1	C46H88NO10P [M-H]-
847.53	847.529	847.5283	0.826	PA 48:12	C51H77O8P [M-H]-
858.72	858.723	-	-	Unidentified	-
860.64	860.638	860.6388	-0.930	HexCer 42:2	C48H91NO9 [M+Cl]-
869.57	869.569	869.5662	3.220	Isotope of m/z 868.563, PC 40:6	C48H84NO8P [M+Cl]-
872.64	872.638	872.6386	-0.688	PS 42:1	C48H92NO10P [M-H]-
880.52	880.519	880.5195	-0.568	HexCer 32:3	C44H79NO14 [M+Cl]-
910.55	914.584	914.5845	-0.547	Isotope of m/z 913.585, PI 40:4	С49Н87О13Р [М-Н]-
976.62	976.619	976.6204	-1.434	PE 50:9	C55H92NO9P [M+Cl]-